A Study Investigating the Safety of RO7795081 and How the Body Processes RO7795081 in People With Normal or Decreased Kidney Functions
2026年9月10日 更新者：Hoffmann-La Roche
A Two-part, Non-randomized, Open-label, Parallel-group Study to Assess the Effect of Renal Impairment on the Pharmacokinetics and Safety of RO7795081 Following a Single Oral Dose of RO7795081
The purpose of this study is to assess the effect of renal impairment on the pharmacokinetics (PK) and safety of RO7795081, following a single oral dose in participants with renal impairment compared with participants with normal renal function.
In Part 1, participants with normal renal function and participants with severe renal impairment or kidney failure not receiving dialysis will receive RO7795081. Part 2 is optional and will be conducted based on the results of Part 1. If Part 2 is implemented, additional participants with normal renal function and participants with mild or moderate renal impairment may be enrolled to receive RO7795081.
研究概览
研究类型
介入性
注册 (估计的)
60
阶段
- 阶段1
联系人和位置
本节提供了进行研究的人员的详细联系信息，以及有关进行该研究的地点的信息。
学习联系方式
- 姓名：Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry
研究联系人备份
- 姓名：Reference Study ID Number: BP46039 https://forpatients.roche.com/ No attachments to email below.
- 电话号码：888-662-6728
- 邮箱：global-roche-genentech-trials@gene.com
学习地点
-
-
Florida
-
Miami Lakes、Florida、美国、33014
- 招聘中
- Panax Clinical Research, LLC
-
St. Petersburg、Florida、美国、33705
- 招聘中
- GCP Research - Florida
-
-
参与标准
研究人员寻找符合特定描述的人，称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
适合学习的年龄
- 成人
- 年长者
接受健康志愿者
是的
描述
Inclusion Criteria:
- Ability and willingness to comply with all aspects of the protocol including completion of assessments for the duration of the study
- Estimated Glomerular Filtration Rate (eGFR) calculated using the Body Surface Area (BSA)-adjusted Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation
- Participants with mild, moderate, or severe renal impairment/kidney failure and stable renal function
- Participants with normal renal function matched to participants with renal impairment
Exclusion Criteria:
- Any condition or disease detected during the medical interview/physical examination that would render the participant unsuitable for the study, place the participant at undue risk, or interfere with the ability of the participant to complete the study in the opinion of the Investigator
- History or evidence of any medical condition other than renal impairment capable of significantly altering the absorption, metabolism, or elimination of drugs
- Surgical history of the gastrointestinal (GI) tract affecting gastric motility or altering the GI tract (with the exception of uncomplicated appendectomy and cholecystectomy)
- History of malignancy in the past 5 years, except for fully treated local basal carcinoma, or fully treated carcinoma in situ of cervix
- Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2
- History of cardiovascular, neurologic, psychiatric, or infectious disease
- History of hypersensitivity to any of the excipients in Glucagon-like Peptide-1 (GLP-1) agonists
- Bipolar disorder, schizophrenia, or any other serious psychiatric condition
- Type 1 diabetes or poorly controlled Type 2 diabetes
- Current or recent participation in another clinical study
- Pregnancy or breastfeeding
- Positive Human Immunodeficiency Virus (HIV), hepatitis B, hepatitis C, or tuberculosis test
- History of alcohol or substance abuse
学习计划
本节提供研究计划的详细信息，包括研究的设计方式和研究的衡量标准。
研究是如何设计的？
设计细节
- 主要用途：治疗
- 分配：非随机化
- 介入模型：并行分配
- 屏蔽：无（打开标签）
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的：Group 1: Participants with Normal Renal Function, RO7795081
Participants with normal renal function will receive a single oral dose of RO7795081.
|
Participants will receive RO7795081 as per the schedule described in the protocol.
其他名称：
|
|
实验性的：Group 2: Participants with Severe Renal Impairment, RO7795081
Participants with severe renal impairment or kidney failure not receiving dialysis will receive a single oral dose of RO7795081.
|
Participants will receive RO7795081 as per the schedule described in the protocol.
其他名称：
|
|
实验性的：Group 3: Participants with Moderate Renal Impairment, RO7795081
Participants with moderate renal impairment will receive a single oral dose of RO7795081.
|
Participants will receive RO7795081 as per the schedule described in the protocol.
其他名称：
|
|
实验性的：Group 4: Participants with Mild Renal Impairment, RO7795081
Participants with mild renal impairment will receive a single oral dose of RO7795081.
|
Participants will receive RO7795081 as per the schedule described in the protocol.
其他名称：
|
研究衡量的是什么？
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
Maximum Plasma Concentration (Cmax) of RO7795081
大体时间：At prespecified timepoints from Day 1 to Day 14
|
At prespecified timepoints from Day 1 to Day 14
|
|
Area Under the Plasma Concentration-Time Curve (AUC) From Time 0 to the Last Measurable Concentration (AUClast) of RO7795081
大体时间：At prespecified timepoints from Day 1 to Day 14
|
At prespecified timepoints from Day 1 to Day 14
|
|
AUC From Time 0 to Infinity (AUCinf) of RO7795081
大体时间：At prespecified timepoints from Day 1 to Day 14
|
At prespecified timepoints from Day 1 to Day 14
|
次要结果测量
结果测量 |
大体时间 |
|---|---|
|
Incidence and Severity of Adverse Events
大体时间：Baseline up to Day 14
|
Baseline up to Day 14
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
调查人员
- 研究主任：Clinical Trials、Hoffmann-La Roche
出版物和有用的链接
负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查，以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始 (实际的)
2026年9月9日
初级完成 (估计的)
2028年2月1日
研究完成 (估计的)
2028年2月1日
研究注册日期
首次提交
2026年7月29日
首先提交符合 QC 标准的
2026年7月29日
首次发布 (实际的)
2026年8月3日
研究记录更新
最后更新发布 (实际的)
2026年9月11日
上次提交的符合 QC 标准的更新
2026年9月10日
最后验证
2026年9月1日
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- BP46039
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)？
不
药物和器械信息、研究文件
研究美国 FDA 监管的药品
是的
研究美国 FDA 监管的设备产品
不
此信息直接从 clinicaltrials.gov 网站检索，没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求，请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改，我们的网站上也会自动更新.